Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure

Patent metadata

Field	Value
Publication number	US-9526747-B2
Application number	US-201113301186-A
Country	US
Kind code	B2
Filing date	Nov 21, 2011
Priority date	Aug 5, 1999
Publication date	Dec 27, 2016
Grant date	Dec 27, 2016

Abstract

The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells in cardiac indications.

First claim

What is claimed is:

1. A method of providing cardiac muscle to a subject in need thereof, said method comprising administering to the subject, in an amount effective to provide new cardiac muscle, isolated expanded human multipotent non-ES, non-germ cells that express telomerase, have the capacity to undergo 40 cell doublings in culture and have a normal karyotype, wherein the existing cardiac muscle is damaged by disease or injury.

2. The method of claim 1 wherein the non-embryonic, non-germ cells further express one or more of oct4, rex-1, rox-1, or sox-2.

3. The method of either of claims 1 or 2 , wherein the disease is selected from the group consisting of congestive heart failure, coronary artery disease, myocardial infarction, myocardial ischemia, atherosclerosis, cardiomyopathy, idiopathic cardiomyopathy, cardiac arrhythmias, muscular dystrophy, muscle mass abnormality, muscle degeneration, infective myocarditis, drug- or toxin-induced muscle abnormalities, hypersensitivity myocarditis, autoimmune endocarditis, and congenital heart disease.

4. The method of claim 1 wherein the cells are derived from bone marrow.

5. The method of claim 1 wherein the cells have undergone 10-40 cell doublings in culture.

6. The method of claim 1 wherein the cells can differentiate into at least one cell type of at least two of the endodermal, ectodermal and mesodermal embryonic lineages.

7. The method of claim 6 wherein the cells can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages.

Assignees

• Verfaillie Catherine M
• Reyes Morayma
• Furcht Leo T
• Univ Minnesota

Inventors

• Verfaillie Catherine M
• Reyes Morayma
• Furcht Leo T

Classifications

• C12N2533/52

  Fibronectin; Laminin · CPC title

• C12N2501/135

  Platelet-derived growth factor [PDGF] · CPC title

• C12N2500/38

  Vitamins · CPC title

• C12N2501/235

  Leukemia inhibitory factor [LIF] · CPC title

• C12N2501/105

  Insulin-like growth factors [IGF] · CPC title